Pediatric ODAC Panel Wrestles with New Cancer Paradigm
By Mari Serebrov
Tuesday, November 5, 2013
All the hurdles in developing drugs to fight cancer in children came to the fore as the Pediatric Oncology Subcommittee of the FDA’s Oncology Drugs Advisory Committee grappled with the unknowns of science and a pressing unmet need as they discussed development plans for Bristol-Myers Squibb Co.’s nivolumab, Merck Sharp and Dohme’s MK-3475 and Novartis Pharmaceuticals Corp.’s LEE011.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.